Compare EVEX & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVEX | SCTX |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 582.0M | 536.5M |
| IPO Year | 2020 | 2026 |
| Metric | EVEX | SCTX |
|---|---|---|
| Price | $1.60 | $17.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | $6.26 | ★ $57.00 |
| AVG Volume (30 Days) | ★ 1.1M | 441.9K |
| Earning Date | 11-05-2026 | 11-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.41 | $13.50 |
| 52 Week High | $5.16 | $39.60 |
| Indicator | EVEX | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.41 | 38.49 |
| Support Level | $1.41 | $13.50 |
| Resistance Level | $2.81 | $22.07 |
| Average True Range (ATR) | 0.12 | 2.23 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 73.02 | 23.90 |
Eve Holding Inc is a provider of Urban Air Mobility solutions. The company's operating segments are; eVTOL that includes; the design and production of electric vertical take-off and landing vehicles (eVTOLs) including fixed wing and helicopter operators, as well as lessors that purchase and manage aircraft on behalf of operators; Service and Operations Solutions segment which includes a portfolio of maintenance and support services focused on its and third-party eVTOLs; and the UATM segment, a new Urban Air Traffic Management system designed to allow eVTOLs to operate safely and efficiently in dense urban airspace alongside conventional aircraft and drones.
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.